Skip to playerSkip to main content
Benzinga
  • 1 hour ago
Johnson & Johnson beat Q1 estimates with adjusted EPS of $2.70 and revenue of $24.1B, up nearly 10% year over year. Cancer drug Darzalex generated $4B and psoriasis treatment Tremfya brought in $1.6B, both topping estimates. Autoimmune drug Stelara fell ~60% to $656M amid biosimilar competition. J&J raised its 2026 revenue forecast to $100.8B and EPS outlook to $11.55.
Transcript
00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Johnson & Johnson beat first quarter earnings expectations and raised its full year forecast
00:07as strong demand for its cancer drug and psoriasis treatment
00:11offset a sharp decline in sales for its autoimmune drug, according to CNBC.
00:16Johnson & Johnson reported adjusted earnings of $2.70 per share on $24.1 billion in revenue,
00:23beating estimates of $2.66 per share and $23.6 billion.
00:29Revenue rose nearly 10% year-over-year.
00:31The company's autoimmune drug, Stellara, lost patent protection and faces biosimilar competition,
00:37driving a roughly 60% year-over-year sales decline to $656 million.
00:42Tremphia J&J's psoriasis drug generated $1.6 billion,
00:47and the cancer drug, Darzalex, brought in $4 billion, both exceeding analyst expectations.
00:53The company raised its 2026 revenue forecast midpoint to about $100.8 billion
00:59and lifted its adjusted earnings outlook to $11.55 per share.
01:04For all things money, visit Benzinga.com.
Comments